Supplemental Benefit of Angiotensin II Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan (SUPPORT Trial)
Phase of Trial: Phase III
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Olmesartan medoxomil (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- Acronyms SUPPORT
- 15 Nov 2017 Results (n=554) presented at the 90th Annual Scientific Sessions of the American Heart Association.
- 10 Jun 2017 Biomarkers information updated
- 15 Sep 2016 Results (n=1138) of a subanlysis of SUPPORT trial assessing the influence of Left Ventricular Ejection Fraction on the effects of olmesartan in heart failure, published in the Circulation Journal.